Market capitalization | $1.70b |
Enterprise Value | $1.24b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 42.51 |
EV/Sales (TTM) EV/Sales | 14.57 |
P/S ratio (TTM) P/S ratio | 19.96 |
P/B ratio (TTM) P/B ratio | 2.35 |
Revenue growth (TTM) Revenue growth | -41.37% |
Revenue (TTM) Revenue | $85.16m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a Xencor, Inc. forecast:
12 Analysts have issued a Xencor, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 85 85 |
41%
41%
|
|
Gross Profit | 73 73 |
46%
46%
|
|
EBITDA | -204 -204 |
50%
50%
|
EBIT (Operating Income) EBIT | -216 -216 |
48%
48%
|
Net Profit | -198 -198 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Head office | United States |
CEO | Bassil Dahiyat |
Employees | 280 |
Founded | 1997 |
Website | www.xencor.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.